The presence of pamidronate in bone cement affects serum biochemical markers in the rat

• Autorzy: Matuszewski L. , Matuszewska A. , Jaszek M. , Stefaniuk D. , Grzywnowicz K. , Mazurkiewicz T. , Polkowska I.
• Języki publikacji: EN

Abstrakty

EN

The main aim of the study was to assess whether the presence of biphosphate Pamidronate (PA) in the cement implanted into the tibial bones had any effect on the chosen biochemical markers in rat's serum characterising homeostasis. Forty adult male Wistar rats were divided into two control groups and two experimental groups. Tibial bone of rats in the experimental groups was implanted with PA-enriched cement, whereas the bone in control-group's rats was implanted with cement without PA. Serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK) were determined three and six weeks after the surgery. Statistically significant differences in the activities of AST and CK of the rats after implantation with non-enriched cement when compared to rats given PA-enriched cement implantation, were tound. Six weeks after treatment, AST levels decreased significantly in rats with PA-enriched cement, whereas rats in the control group (implanted with non-enriched cement) demonstrated a significant increase in AST activity in comparison to the same values determined after three weeks and values of PA-enriched cement rats determined after six weeks. The activities of CK were higher in rats with PA-enriched implants than in the control group three weeks after surgery, but six weeks after the treatment, rats implanted with enriched cement reached lower values than animals implanted with non-enriched cement. The use of PA in the cement had also some positive effect on the homeostasis of the rats after the surgery and a positive influence on the post operative muscle regeneration process.

• Wydawca: -
• Czasopismo: Bulletin of the Veterinary Institute in Puławy
• Rocznik: 2014
• Tom: 58
• Numer: 2
• Opis fizyczny: p.295-299,fig.,ref.

Twórcy

autor

Matuszewski L.

• Pediatric Orthopedic and Rehabilitation Clinic, Medical University of Lublin, 20-093 Lublin, Poland

autor

Matuszewska A.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Jaszek M.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Stefaniuk D.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Grzywnowicz K.

• Biochemistry Department, Maria-Curie Sklodowska University of Lublin, 20-033 Lublin, Poland

autor

Mazurkiewicz T.

• Orthopaedic and Traumatology Department, Medical University of Lublin, 20-954 Lublin, Poland

autor

Polkowska I.

• Faculty of Veterinary Medicine, University of Life Sciences in Lublin, 20-950 Lublin, Poland

Bibliografia

• 1. Aktas M., Auguste D., Lefebvre H.P., Toutain PL., Braun J.P.: Creatine kinase in the dog: a review. Vet Res Commun 1993, 17, 353-369.
• 2. Aktas M., Auguste D., Concordet D., Vinclair P., Lefebvre H., Toutain P.L., Braun J.P.: Creatine kinase in dog plasma: preanalytical factors of variation, reference values and diagnostic significance. Res Vet Sci 1994, 56, 30-36.
• 3. Aktas M., Lefebvre H.P., Toutain P.L., Braun J.P.: Disposition of creatine kinase activity in dog plasma following intravenous and intramuscular injection of skeletal muscle homogenates. J Vet Pharmacol Ther 1995, 18, 1-6.
• 4. Amelink G.J., Kamp H.H., Bar P.R.: Creatine kinase isoenzyme profiles after exercise in the rat: sex-linked differences in leakage of CK-MM. Pflugers Arch 1988, 412, 417-421.
• 5. Åstrand J., Aspenberg P.: Reduction of instability induced bone resorption using bisphosphonates. High doses are needed in rats. Acta Orthop Scand 2002, 73, 24-30.
• 6. Barbier A., Breliere J.C., Remandet B., Roncucci R.: Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986, 45, 67-74.
• 7. Benfold H.L., Frich J.C., Auriola S., Monkkonen J., Rogers M.J.: Famesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56, 131-140.
• 8. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C., Man Z., Mautalen C., Mesenbrink P.. Hu H., Caminis J., Tong K., Rosario-Jansen T., Krasnow J., Hue T.F., Sellmeyer D., Eriksen E.F., Cummings S.R.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356, 1809-1822.
• 9. Calsey J.D., King D.J.: Clinical chemical values for some common laboratory animals. Clin Chem 1980, 26, 1877-1879.
• 10. Drake M.T., Clarke B.L., Khosla S.: Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc, 2008, 83, 1032-1045.
• 11. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Kaff R.S., Seeff L.B.: Diagnosis and monitoring of hepatic injurv. I. Performance characteristics of laboratory tests. Clin Chem 2000, 46, 2027-2049.
• 12. Fleisch H.: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19, 80-100.
• 13. Francis M.D., Hovancik K., Boyce R.W.: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989, 11, 239-252.
• 14. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gammadichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12, 1358-1367.
• 15. Geoffroy V., Paschalis E.P., Libouban H., Blouin S., Ostertag A., Chappard D., Cros M., Phipps R, de Vemejoul M.C.: Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. Calcif Tissue Int 2011, 88, 464-475.
• 16. Goodship A.E., Blunn G.W., Green J., Coathup M.J.: Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate. J Orthop Res 2008, 26, 693- 703.
• 17. Laterza O.F., Lim L., Garret-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., Johnson J.M., Sina J.F., Fare T.L., Sistare F.D., Giaab E.: Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 1983, 55, 1977- 1983.
• 18. Lewis G., Janna S.: Alendronate in bone cement. Clin Orthop Rel Res 2006, 445, 233-238.
• 19. Maksymowych W.P.: Bisphosphonates Anti-inflammatory properties. Curr Med Chem - Anti-Inflammatory & Anti-Allergy Agents 2002, 1, 15-28.
• 20. Matuszewski Ł., Matuszewska A., Jaszek M., Grąz M., Mazurkiewicz T., Gągała J., Polkowska I.: Determination of pamidronate in bisphosphonate-enriched cement implanted in rats by ion-pair HPLC and capillary electrophoresis. Bull Vet Inst Pulawy 2013, 57, 257-262.
• 21. Matuszewski Ł., Turżańska K., Matuszewska A., Jabłoński M., Polkowska I., Mazurkiewicz T.: Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography. Int Orthop 2013, 37, 1187-1193.
• 22. Matuszewski Ł., Olchowik G., Mazurkiewicz T., Kowalczyk B., Zdrojewska A., Matuszewska A., Ciszewski A., Gospodarek M., Morawik I.: Biomechanical parameters of the BP-enriched bone cement. Eur J Orthop Surg Traumatol 2013, DOI 10.1007/s00590- 013-1230-I.
• 23. Mazurkiewicz T., Matuszewski Ł., Matuszewska A., Jaszek M.: Implanted bisphosphonates in bone cement affect bone markers in rat serum. Int Orthop 2013, 37, 969-974.
• 24. Moss D.W., Henderson A.R: Enzymes, In: Fundamentals of Clinical Chemistry, Burtis C.A., Ashworth E.R., W.B. Saunders Company, Philadelphia 1996, pp. 283-335.
• 25. Osterman T., Kippo K., Lauren L., Hannuniemi R., Sellman R.: Effect of clodronate on established adjuvant arthritis. Rheumatol Int 1994, 14, 139-147.
• 26. Pennanen N., Lapinjoki S., Urti A., Monkkonen J.: Effect of liposomal and free bisphosphonates on the IL-1 ß, IL-6 and TNF secretion from RAW 264 cells in vitro. Pharm Res 1995, 12, 916- 922.
• 27. Qi M., Hu J., Li J., Li J., Dong W., Feng X., Yu J.: Effect of zoledronate acid treatment on osteointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits. Bone 2012, 50, 119-27.
• 28. Schindeler A., Birke O., Yu N.Y., Morse A., Ruys A., Baldock P.A., Little D.G.: Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate. J Bone Joint Surg Br 2011, 93, 1134-1139.
• 29. Schlattner U., Schlattner-Tokaska M., Wallimann T.: Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta 2006, 1762, 164-180.
• 30. Viereck V., Emons G., Lauck V., Frosch K-H., Blaschke S., Grundker C., Hofbauer L.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291, 680-686.